Cormorant Asset Management, LP
CIK: 0001583977Latest portfolio: $2.2B · Q4 2025
Holdings
35
Total Value
$2.2B
New Positions
6
Closed Positions
7
Top Holdings
View All 35 Holdings →| # | Stock | Shares | Value | % Portfolio | Change | Type |
|---|---|---|---|---|---|---|
| 1 | PRAXPRAXIS PRECISION MEDICINES I | 950,000 | $280.0M | 12.95% | -50,000 | |
| 2 | BBOTBRIDGEBIO ONCOLOGY THERAPEUT | 17,878,594 | $223.8M | 10.35% | — | |
| 3 | ABVXABIVAX SA | 1,350,000 | $182.1M | 8.42% | -600,000 | |
| 4 | NDQINVESCO QQQ TR | 250,000 | $153.6M | 7.10% | NEW | Put |
| 5 | EYPTEYEPOINT INC | 8,265,000 | $151.0M | 6.98% | -60,000 | |
| 6 | IWMISHARES TR | 500,000 | $123.1M | 5.69% | NEW | Put |
| 7 | XBISPDR SERIES TRUST | 1,000,000 | $121.9M | 5.64% | NEW | Put |
| 8 | RAPPRAPPORT THERAPEUTICS INC | 3,027,521 | $91.9M | 4.25% | -165,000 | |
| 9 | BBIOBRIDGEBIO PHARMA INC | 1,200,000 | $91.8M | 4.24% | -200,000 | |
| 10 | DRUGBRIGHT MINDS BIOSCIENCES INC | 1,059,331 | $82.7M | 3.82% | — | |
| 11 | EWTXEDGEWISE THERAPEUTICS INC | 3,285,000 | $81.5M | 3.77% | -725,000 | |
| 12 | OLMAOLEMA PHARMACEUTICALS INC | 2,750,000 | $68.8M | 3.18% | NEW | |
| 13 | MLTXMOONLAKE IMMUNOTHERAPEUTICS | 4,355,433 | $57.4M | 2.65% | +2.4M | |
| 14 | IM8NINSMED INC | 275,000 | $47.9M | 2.21% | -155,000 | |
| 15 | ENGNENGENE HOLDINGS INC | 4,000,000 | $36.1M | 1.67% | +1.7M | |
| 16 | ALMSALUMIS INC | 3,635,596 | $35.5M | 1.64% | +1.5M | |
| 17 | MBXMBX BIOSCIENCES INC | 1,120,000 | $35.3M | 1.63% | -105,000 | |
| 18 | NAMSNEWAMSTERDAM PHARMA COMPANY | 1,000,000 | $35.1M | 1.62% | -1,175,000 | |
| 19 | CNTACENTESSA PHARMACEUTICALS PLC | 1,325,000 | $33.1M | 1.53% | -600,000 | |
| 20 | PHVSPHARVARIS N V | 1,083,000 | $30.1M | 1.39% | -280,200 | |
| 21 | BIOABIOAGE LABS INC | 2,040,605 | $27.0M | 1.25% | -100,000 | |
| 22 | ASNDASCENDIS PHARMA A/S | 100,000 | $21.3M | 0.99% | NEW | |
| 23 | TARSTARSUS PHARMACEUTICALS INC | 250,000 | $20.5M | 0.95% | -50,000 | |
| 24 | CRBPCORBUS PHARMACEUTICALS HLDGS | 2,344,971 | $19.1M | 0.88% | -30,029 | |
| 25 | GHRSGH RESEARCH PLC | 1,300,000 | $16.5M | 0.76% | -616,439 |
Quarterly Changes
Sector Breakdown
Healthcare0.0% ($2.800032238391821e+142T)
Financial Services0.0% ($123.1T)
Unknown0.0% ($15.4T)
Filing History
| Quarter | Filing Date | Portfolio Value | Holdings |
|---|---|---|---|
| Q4 2025 | Feb 17, 2026 | $2.2B | 35 |
| Q3 2025 | Nov 14, 2025 | $1.4T | 36 |
| Q2 2025 | Aug 14, 2025 | $1.3T | 42 |
| Q1 2025 | May 15, 2025 | $1.3T | 44 |
| Q4 2024 | Feb 14, 2025 | $1.8T | 48 |
| Q3 2024 | Nov 14, 2024 | $1885.8T | 45 |
| Q2 2024 | Aug 14, 2024 | $1731.1T | 49 |
| Q1 2024 | May 15, 2024 | $2279.6T | 57 |
| Q4 2023 | Feb 14, 2024 | $2093.9T | 48 |
| Q3 2023 | Nov 14, 2023 | $1714.3T | 49 |
| Q2 2023 | Aug 14, 2023 | $1785.1T | 64 |
| Q1 2023 | May 15, 2023 | $1.5T | 72 |
| Q4 2022 | Feb 14, 2023 | $1.5T | 73 |
| Q3 2022 | Nov 14, 2022 | $1.4T | 73 |
| Q2 2022 | Aug 15, 2022 | $1.3T | 80 |
| Q1 2022 | May 16, 2022 | $1.3T | 77 |
| Q4 2021 | Feb 14, 2022 | $1.7T | 78 |
| Q3 2021 | Nov 15, 2021 | $2.5T | 88 |
| Q2 2021 | Aug 16, 2021 | $2.9T | 104 |
| Q1 2021 | May 17, 2021 | $4.5T | 120 |
| Q4 2020 | Feb 16, 2021 | $4.2T | 105 |
| Q3 2020 | Nov 16, 2020 | $2.6T | 93 |
| Q2 2020 | Aug 14, 2020 | $2.6T | 81 |
| Q1 2020 | May 15, 2020 | $2.2T | 73 |
| Q4 2019 | Feb 14, 2020 | $2.5T | 67 |
| Q3 2019 | Nov 14, 2019 | $1.6T | 75 |
| Q2 2019 | Aug 14, 2019 | $1.7T | 72 |
| Q1 2019 | May 15, 2019 | $1.5T | 64 |
| Q4 2018 | Feb 14, 2019 | $1.2T | 70 |
| Q3 2018 | Nov 14, 2018 | $1.5T | 65 |
| Q2 2018 | Aug 14, 2018 | $1.4T | 58 |
| Q1 2018 | May 15, 2018 | $1.3T | 52 |
| Q4 2017 | Feb 14, 2018 | $955.3B | 52 |
| Q3 2017 | Nov 14, 2017 | $566.4B | 51 |
| Q2 2017 | Aug 14, 2017 | $603.3B | 71 |
| Q1 2017 | May 15, 2017 | $688.7B | 75 |
| Q4 2016 | Feb 14, 2017 | $741.8B | 77 |
| Q3 2016 | Nov 14, 2016 | $906.8B | 84 |
| Q2 2016 | Aug 15, 2016 | $705.2B | 84 |
| Q1 2016 | May 16, 2016 | $2.0T | 84 |
Fund Information
Cormorant Asset Management, LP is an institutional investment manager that files 13F reports with the SEC. As of the Q4 2025 filing, the fund reported a portfolio valued at $2.2B across 35 holdings. The largest position is PRAXIS PRECISION MEDICINES I (PRAX), representing 12.9% of the portfolio. Compared to the previous quarter, the fund opened 6 new positions and closed 7 positions. 13F filings are required quarterly disclosures that provide transparency into the holdings of institutional investment managers with at least $100 million in qualifying assets.